Pathology of the myeloproliferative diseases

Hematology/Oncology Clinics of North America

Volumn 17, Issue 5, 2003, Pages 1101-1127

  George, Tracy I ^a   Arber, Daniel A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CD19 ANTIGEN; CD33 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ERYTHROPOIETIN; HYDROXYUREA; IMATINIB; MICROSOMAL AMINOPEPTIDASE; PROTEIN TYROSINE KINASE INHIBITOR;

CHILDHOOD LEUKEMIA; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DISEASE CLASSIFICATION; HISTOPATHOLOGY; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOCYTHEMIA;

EID: 0141730229     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00093-5     Document Type: Review

References (158)

1. Jaffe ES, Harris NL, Stein H, Vardiman JS, editors. World Heatlh Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 15-106.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
3. Verfaillie CM. Biology of chronic myelogenous leukemia. Hematol Oncol Clin N Am 1998;12:1-29.
4. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
5. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian M. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72.
6. Melo JV. The molecular biology of chronic myeloid leukaemia. Leukemia 1996;10(Suppl. 2): S4-9.
7. Thiele J, Kvasnicka HM, Titius BR, et al. Histological features of prognostic significance in CML - an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann Hematol 1993;66:291-302.
8. Büsche G, Majewski H, Schlué J, et al. Frequency of pseudo-Gaucher cells in diagnostic bone marrow biopsies from patients with Ph-positive chronic myeloid leukaemia. Virchows Arch 1997;430:139-48.
9. Arlin ZA, Silver RT, Bennett JM. Blastic phase of chronic myeloid leukemia (blCML): a proposal for standardization of diagnostic and response criteria. Leukemia 1990;4:755-7.
10. Ross DW, Brunning RD, Kantarjian HM, Koeffler P, Ozer H. A proposed staging system for chronic myeloid leukemia. Cancer 1993;71:3788-91.
11. Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology; 1994.
12. Mitelman F, Levan G, Nilsson PG, Brandt L. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer 1976;18:24-30.
13. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 1993;11(Suppl 1):11-5.
14. Khalidi HS, Brynes RK, Medeiros LJ, et al. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and a comparison of morphologic, immunophenotypic, and molecular findings. Mod Pathol 1998;11:1211-21.
15. Cervantes F, Villamor N, Esteve J, et al. 'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol 1998;100:123-8.
16. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia: Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features. Am J Clin Pathol 2000;114:57-65.
17. Facchetti F, Tironi A, Marocolo D, et al. Histopathological changes in bone marrow biopsies from patients with chronic myeloid leukaemia after treatment with recombinant alpha-interferon. Histopathology 1997;31:3-11.
18. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
19. Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002;117:360-7.
20. Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months experience. Blood 2002;100:435-41.
21. Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99:381-3.
22. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996;88:2410-4.
23. Verstovsek S, Lin H, Kantarjian H, et al. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 2002;94:2416-25.
24. Wiedemann LM, Karhi KK, Shivji MKK, et al. The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases. Blood 1988;71:349-55.
25. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-64.
26. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999;36(Suppl 2):9-13.
27. Messinezy M, Pearson TC. Diagnosis of polycythaemia. J Clin Pathol 1998;51:1-4.
28. Johansson P, Safai-Kutti S, Lindstedt G, Suurkula M, Kutti J. Red cell mass, spleen size and plasma erythropoietin in polycythaemia vera and apparent polycythaemia. Acta Haematol 2002;108:1-7.
29. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-51.
30. Pearson TC, Messinezy M. The diagnostic criteria for polycythaemia rubra vera. Leuk Lymphoma 1996;22(Suppl 1):87-93.
31. Ellis JT, Peterson P, Geller SA, Rapport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986;23:144-55.
32. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001;86:368-74.
33. Thiele J, Kvasnicka HM, Muehlhausen K, Walter S, Zankovich R, Diehl V. Polycythemia rubra vera versus secondary polycythemias: a clinicopathological evaluation of distinctive features in 199 patients. Pathol Res Pract 2001;197:77-84.
34. Thiele J, Zirbes TK, Kvasnicka HM, Fischer R. Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma - a practical guideline. J Clin Pathol 1999;52:294-300.
35. Najean Y, Deschamps A, Dresch C, Daniel MT, Rain JD, Arrago JP. Acute leukemia and myelodysplasia in polycythemia vera: a clinical study with long-term follow-up. Cancer 1988;61:89-95.
36. Diez-Martin JL, Graham DL, Pettit RM, DeWald GW. Chromosomes studies in 104 patients with polycythemia vera. Mayo Clin Proc 1991;66:287-99.
37. Asimakopoulos FA, Gilbert JGR, Aldred MA, Pearson TC, Green AR. Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood 1996;88:2690-8.
38. Asimakopoulos FA, Green AR. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 1996;95:219-26.
39. Prchal JF, Prchal JT. Molecular basis for polycythemia. Curr Opin Hematol 1999;6:100-9.
40. Zwicky C, Theiler L, Zbaren K, Ischi E, Tobler A. The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera. Br J Haematol 2002;117:598-604.
41. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002;99:1144-9.
42. Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000;95:2569-76.
43. Klippel S, Strunck E, Busse CE, Behringer D, Pahl HL. Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood 2002;100:2441-8.
44. Teofili L, Martini M, Luongo M, et al. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. J Clin Oncol 2002;20:4249-54.
45. Hasselbalch H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 1990;34:291-300.
46. Thiele J, Kvasnicka H-M, Werden C, Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution, differentiation from essential thrombocythemia and variable of prognostic impact. Leuk Lymphoma 1996;22:303-17.
47. Manoharan A. Idiopathic myelofibrosis: a clinical review. Int J Hematol 1998;68:355-62.
48. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-65.
49. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133-45.
50. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Early-stage idiopathic (primary) myelofibrosis - current issues of diagnostic features. Leuk Lymphoma 2002;43:1035-41.
51. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001;80:160-5.
52. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)-a clinicopathological study. Leukemia 1999;13:1741-8.
53. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1999;33:207-18.
54. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 2000;85:1126-34.
55. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189-94.
56. Barosi G, Ambrosetti A, Finelli C, et al. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999;104:730-7.
57. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report of 195 cases with a new scoring system. Blood 1996;88:1013-8.
58. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997;98:96-102.
59. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thromobocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29-39.
60. Kutti J, Wadenvik H. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 1996;22(Suppl 1):41-5.
61. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 1997;23:339-47.
62. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-24.
63. Nimer SD. Essential thrombocythemia: another "heterogenous disease" better understood? Blood 1999;93:415-6.
64. Thiele J, Schneider G, Hoeppner B, Wienhold S, Zankovich R, Fischer R. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders wtih associated thrombocytosis-features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch A Pathol Anat 1988;413:407-17.
65. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-4.
66. Sterkers Y, Preudhomme C, Lai J-L, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-22.
67. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogeneic myeloid metaplasia: an Olmsted county study, 1976-1995. Am J Hematol 1999;61:10-5.
68. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 2002;70:283-91.
69. Mi JQ, Blanc-Jouvan F, Wang J, et al. Endogenous megakaryocytic colony formation and thrombopoietin sensitivity of megakaryocytic progenitor cells are useful to distinguish between essential thrombocythemia and reactive thrombocytosis. J Hematother Stem Cell Res 2001;10:405-9.
70. Mesa RA, Hanson CA, Li CY, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mp1 expression in essential thrombocythemia. Blood 2002;99:4131-7.
71. Aviram A, Blickstein D, Stark P, et al. Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leuk Lymphoma 1999;33:77-82.
72. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises: case 17-1992: repeated bouts of hematochezia in an 80-year-old hypertensive man. N Engl J Med 1992;326:1137-46.
73. Gupta R, Abdalla SH, Bain BJ. Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome. Leuk Lymphoma 1999;34:615-9.
74. Koike T, Uesugi Y, Toba K, et al. 5q-syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders? Leukemia 1995;9:517-8.
75. You W, Weisbrot IM. Chronic neutrophilic leukemia: report of two cases and review of the literature. Am J Clin Pathol 1979;72:233-42.
76. Zittoun R, Rea D, Ngoc LH, Ramond S. Chronic neutrophilic leukemia: a study of four cases. Ann Hematol 1994;68:55-60.
77. Hasle H, Olesen G, Kemdrup G, Philip P, Jacobsen N. Chronic neutrophil leukaemia in adolescence and young adulthood. Br J Haematol 1996;94:628-30.
78. Elliott MA, DeWald GW, Tefferi A, Hanson CA. Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia 2001;15:35-40.
79. Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol 2002;116:10-8.
80. Tursz T, Flandrin G, Brouet JC, Seligmann M. [Coexistence of a myeloma and a granulocytic leukemia in the absence of any treatment: study of 4 cases]. Nouv Rev Fr Hematol 1974;14:693-704.
81. Cehreli C, Undar B, Akkoc N, Onvural B, Altungoz O. Coexistence of chronic neutrophilic leukemia with light chain myeloma. Acta Haematol 1994;91:32-4.
82. Standen GR, Jasani B, Wagstaff M, Wardrop CA. Chronic neutrophilic leukemia and multiple myeloma: an association with lambda light chain expression. Cancer 1990;66:162-6.
83. Dincol G, Nalcaci M, Dogan O, et al. Coexistence of chronic neutrophilic leukemia with multiple myeloma. Leuk Lymphoma 2002;43:649-51.
84. Katsuki K, Shinohara K, Takeda K, et al. Chronic neutrophilic leukemia with acute myeloblastic transformation. Jpn J Clin Oncol 2000;30:362-5.
85. Bain BJ. Eosinophilic leukemia and the idiopathic hypereosinophilic syndrome. Br J Haematol 1996;95:2-9.
86. Bain BJ. Eosinophilia - idiopathic or not? N Engl J Med 1999;341:1141-3.
87. Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000;7:21-5.
88. Chang H-W, Leong K-H, Koh D-R, Lee S-H. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999;93:1651-7.
89. Baranger L, Szapiro N, Gardais J, et al. Translocation t(5;12)(q31-q33;p12-p13): a non-random translocation associated with a myeloid disorder with eosinophilia. Br J Haematol 1994;88:343-7.
90. Berkowicz M, Rosner E, Rechavi G, et al. Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12): a new association. Cancer Genet Cytogenet 1991;51:277-8.
91. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
92. Macdonald D, Aguiar RCT, Mason PJ, Goldman JM, Cross NCP. A new myeloproliferative disorder associated with chromosmal translocations involving 8p11: a review. Leukemia 1995;9:1628-30.
93. Abruzzo LV, Jaffe ES, Cotelingam JD, Whang-Peng J, Del Jr DV, Medeiros LJ. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol 1992;16:236-45.
94. Reiter A, Sohal J, Kulkami S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998;92:1735-42.
95. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998;18:84-7.
96. Neuwirtová R, Mociková K, Musiolová J, et al. Mixed myelodysplastic and myeloproliferative syndromes. Leuk Res 1996;20:717-26.
97. Oscier D. Atypical chronic myeloid leukemias. Pathol Biol 1997;45:587-93.
98. Bennett JM, Catovsky D, Daniel M-T, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonoctic leukaemia: proposals by the French-American-British cooperative leukaemia group. Br J Haematol 1994;87:746-54.
99. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML - dysplastic versus proliferative type. Leuk Res 1998;22:871-8.
100. Voglova J, Chrobak L, Neuwirtova R, Malaskova V, Straka L. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia - distinct subgroups or two stages of the same disease? Leuk Res 2001;25:493-9.
101. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840-9.
102. Gonzalez-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative: prognostic implications in a series of a single center. Leuk Res 2002;26:821-4.
103. Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 1996;33:95-110.
104. Sawyers CL, Denny CT. Chronic myelomonocytic leukemia: tel-a-kinase what ets all about. Cell 1994;77:171-3.
105. Gilliland DG. Molecular genetics of human leukemia. Leukemia 1998;12(Suppl):S7-12.
106. Fenaux P, Beuscart R, Lai J-L, Jouet P, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988;6:1417-24.
107. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet 1991;55:57-65.
108. Fenaux P, Jouet JP, Zandecki M, et al. Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol 1987;65:101-6.
109. Stomiolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia 1990;4:766-70.
110. Tefferi A, Hoagland HC, Themeau TM, Pierre RV. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989;64:1246-54.
111. Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 1992;48:208-14.
112. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis: use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993;100:534-40.
113. Woodlock TJ, Seshi B, Sham RL, Cyran EM, Bennett JM. Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia. Leuk Res 1994;18:173-81.
114. Maynadie M, Picard F, Husson B, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002;100:2349-56.
115. Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993;7:499-508.
116. Haase D, Fonatsch C, Freund M, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 1995;70:171-87.
117. Fenaux P, Morel P, Lai J-L. Cytogenetics of myelodysplastic syndromes. Semin Hematol 1996;33:127-38.
118. McClure RF, DeWald GW, Hoyer JD, Hanson CA. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol 1999;106:445-54.
119. Magnusson MK, Meade KE, Brown KE, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001;98:2518-25.
120. Willman CL. Molecular genetic features of myelodysplastic syndromes (MDS). Leukemia 1998;12(Suppl 1):S2-6.
121. Cogswell PC, Morgan R, Dunn M, et al. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989;74:2629-33.
122. Dobrovic A, Morley AA, Seshadri R, Januszewicz EH. Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: clinical features and course of M-bcr negative and M-bcr positive. Leukemia 1991;5:187-90.
123. Oscier DG. Atypical chronic myeloid leukaemia, a distinct clinical entitity related to the myelodysplastic syndrome? Br J Haematol 1996;92:582-6.
124. Hernandez JM, del Canizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000;11:441-4.
125. Costello R, Sainty D, Larage-Pochitabloff M, Gabert J. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Leuk Lymphoma 1997;25:225-32.
126. Martiat P, Michaux J-L, Rodhain J. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. Blood 1991;78:205-11.
127. Shepherd PC, Ganesan TS, Galton DA. Haematological classification of the chronic myeloid leukaemias. Baillieres Clin Haematol 1987;1:887-906.
128. Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 2001;97:3910-8.
129. Siena S, Sammarelli G, Grimoldi MG, et al. New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia. Haematologica 1999;84:369-72.
130. Kulkami S, Heath C, Parker S, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 2000;60:3592-8.
131. Niemeyer CM, Fenu S, Hasle H, Mann G, Stary J, van Wering E. Differentiating juvenile myelomonocytic leukemia from infectious disease [response]. Blood 1998;91:365-7.
132. Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia. Canada. Br J Haematol 1999;106:1027-32.
133. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995;9:1569-72.
134. Jackson GH, Carey PJ, Cant AJ, Bown NP, Reid MM. Myelodysplastic syndromes in children. Br J Haematol 1993;84:185-6.
135. Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001;15:1713-20.
136. Hasle H, Arico M, Basso G, et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia 1999;13:376-85.
137. Luna-Fineman S, Shannon K, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 1999;93:459-66.
138. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997;90:479-88.
139. Niemeyer CM, Aricó M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood 1997;89:3534-43.
140. Hasle H. Atypical chronic myelojd leukaemia and chronic myelomonocytic leukaemia in children. Br J Haematol 1995;89:428-9.
141. Pinkel D. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998;91:365-7.
142. Emanuel PD. Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol 1999;105:852-63.
143. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology biology, and mechanistic implications. Blood 1995;85:1985-99.
144. Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999;13:32-7.
145. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996;12:137-43.
146. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996;12:144-8.
147. Woods WG, Bamard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia of myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002;20:434-40.
148. Iversen PO, Emanuel PD, Sioud M. Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood 2002;99:4147-53.
149. Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by famesyltransferase inhibitors. Blood 2000;95:639-45.
150. Streeter RR, Presant CA, Reinhard E. Prognostic significance of thrombocytosis in idiopathic sideroblastic anemia. Blood 1977;50:427-32.
151. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM. Essential thrombocythemia with ringed sidero-blasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002;87:392-9.
152. Norrby A, Ridell B, Swolin B, Westin J. Rearrangement of chromosome no. 3 in a case of preleukemia with thrombocytosis. Cancer Genet Cytogenet 1982;5:257-63.
153. Carroll AJ, Poon MC, Robinson NC, Crist WM. Sideroblastic anemia associated with thrombocytosis and a chromosome 3 abnormality. Cancer Genet Cytogenet 1986;22:183-7.
154. Jotterand BM, Parlier V, Muhlematter D, Grob JP, Beris P. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet 1992;59:138-60.
155. Grigg AP, Gascoyne RD, Phillips GL, Horsman DE. Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. Br J Haematol 1993;83:158-65.
156. Fonatsch C, Gudat H, Lengfelder E, et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994;8:1318-26.
157. Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995;91:490-501.
158. Cool J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIPILI genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.